We monitored the tumor burden and serum cytokines in mouse models of solid (MUC16-expressing) or hematologic (BCMA-expressing) malignancies following treatment with CD3-based bsAbs engineered with different CD3 affinities. Here, MUC16 is linked to neoplasm.